Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174399
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Strosberg, Jonathan | - |
dc.contributor.author | Kunz, Pamela L. | - |
dc.contributor.author | Hendifar, Andrew | - |
dc.contributor.author | Yao, James | - |
dc.contributor.author | Bushnell, David | - |
dc.contributor.author | Kulke, Matthew H. | - |
dc.contributor.author | Baum, Richard P. | - |
dc.contributor.author | Caplin, Martyn | - |
dc.contributor.author | Ruszniewski, Philippe | - |
dc.contributor.author | Delpassand, Ebrahim | - |
dc.contributor.author | Hobday, Timothy | - |
dc.contributor.author | Verslype, Chris | - |
dc.contributor.author | Benson, Al | - |
dc.contributor.author | Srirajaskanthan, Rajaventhan | - |
dc.contributor.author | Pavel, Marianne | - |
dc.contributor.author | Mora Salvador, Jaume | - |
dc.contributor.author | Berlin, Jordan | - |
dc.contributor.author | Grande, Enrique | - |
dc.contributor.author | Reed, Nicholas | - |
dc.contributor.author | Seregni, Ettore | - |
dc.contributor.author | Paganelli, Giovanni | - |
dc.contributor.author | Severi, Stefano | - |
dc.contributor.author | Morse, Michael | - |
dc.contributor.author | Metz, David C. | - |
dc.contributor.author | Ansquer, Catherine | - |
dc.contributor.author | Courbon, Frédéric | - |
dc.contributor.author | Al-Nahhas, Adil | - |
dc.contributor.author | Baudin, Eric | - |
dc.contributor.author | Giammarile, Francesco | - |
dc.contributor.author | Taïeb, David | - |
dc.contributor.author | Mittra, Erik | - |
dc.contributor.author | Wolin, Edward | - |
dc.contributor.author | O’Dorisio, Thomas M. | - |
dc.contributor.author | Lebtahi, Rachida | - |
dc.contributor.author | Deroose, Christophe M. | - |
dc.contributor.author | Grana, Chiara M. | - |
dc.contributor.author | Bodei, Lisa | - |
dc.contributor.author | Öberg, Kjell | - |
dc.contributor.author | Polack, Berna Degirmenci | - |
dc.contributor.author | He, Beilei | - |
dc.contributor.author | Mariani, Maurizio F. | - |
dc.contributor.author | Gericke, Germo | - |
dc.contributor.author | Santoro, Paola | - |
dc.contributor.author | Erion, Jack L. | - |
dc.contributor.author | Ravasi, Laura | - |
dc.contributor.author | Krenning, Eric | - |
dc.contributor.author | Netter-1 Study Group | - |
dc.date.accessioned | 2021-02-26T08:51:31Z | - |
dc.date.available | 2021-02-26T08:51:31Z | - |
dc.date.issued | 2020-03-02 | - |
dc.identifier.uri | http://hdl.handle.net/2445/174399 | - |
dc.description.abstract | Purpose: To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate. Methods: In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression. Results: Significantly prolonged median PFS occurred with 177Lu-Dotatate versus octreotide LAR 60 mg in patients with low (< 25%), moderate (25-50%), and high (> 50%) liver tumour burden (HR 0.187, 0.216, 0.145), and normal or elevated ALP (HR 0.153, 0.177), and in the presence or absence of a large target lesion (diameter > 30 mm; HR, 0.213, 0.063). Within the 177Lu-Dotatate arm, no significant difference in PFS was observed amongst patients with low/moderate/high liver tumour burden (P = 0.7225) or with normal/elevated baseline ALP (P = 0.3532), but absence of a large target lesion was associated with improved PFS (P = 0.0222). Grade 3 and 4 liver function abnormalities were rare and did not appear to be associated with high baseline liver tumour burden. Conclusions: 177Lu-Dotatate demonstrated significant prolongation in PFS versus high-dose octreotide LAR in patients with advanced, progressive midgut NET, regardless of baseline liver tumour burden, elevated ALP, or the presence of a large target lesion. Clinicaltrials.gov : NCT01578239, EudraCT: 2011-005049-11. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Springer Nature | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1007/s00259-020-04709-x | - |
dc.relation.ispartof | European Journal of Nuclear Medicine and Molecular Imaging, 2020, vol. 47, num. 10, p. 2372-2382 | - |
dc.relation.uri | https://doi.org/10.1007/s00259-020-04709-x | - |
dc.rights | cc by (c) Strosberg et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Tumors | - |
dc.subject.classification | Càncer de fetge | - |
dc.subject.other | Tumors | - |
dc.subject.other | Liver cancer | - |
dc.title | Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-02-16T13:26:45Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 32123969 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Strosberg2020_Article_ImpactOfLiverTumourBurdenAlkal.pdf | 601.04 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License